Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. FDA for its Abbreviated New Drug Application for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg (base).

The details can be read here.